Kennedy Capital Management’s Abeona Therapeutics ABEO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$6.99M Buy
1,330,788
+90,717
+7% +$563K 0.13% 257
2026
Q2
$7.66M Sell
1,240,071
-23,440
-2% -$129K 0.14% 250
2026
Q1
$5.66M Buy
1,263,511
+213,416
+20% +$1.07M 0.12% 267
2025
Q4
$5.53M Sell
1,050,095
-768
-0.1% -$3.87K 0.12% 278
2025
Q3
$5.55M Buy
1,050,863
+378,860
+56% +$2.4M 0.12% 279
2025
Q2
$3.82M Buy
672,003
+50,240
+8% +$286K 0.09% 335
2025
Q1
$2.96M Buy
+621,763
New +$3.38M 0.07% 370

Other funds holding ABEO

Kennedy Capital Management's ABEO Position: Q3 2026 in Review

Kennedy Capital Management increased its Abeona Therapeutics (ABEO) stake by 7.3% in Q3 2026, buying an estimated $563K and bringing the position to 1,330,788 shares worth $6.99M. The position accounts for 0.13% of the portfolio, ranked #257.

Kennedy Capital Management first reported a position in ABEO in Q1 2025 and has held it in 7 quarters since. The position peaked at $7.66M in Q2 2026. 116 funds tracked by Wall St. Rank hold ABEO as of Q3 2026.

  • Kennedy Capital Management held 1,330,788 shares of Abeona Therapeutics worth $6.99M as of Q3 2026.
  • Kennedy Capital Management bought 90,717 Abeona Therapeutics shares in Q3 2026, an estimated $563K.
  • Abeona Therapeutics made up 0.13% of Kennedy Capital Management's portfolio in Q3 2026, its #257 holding.
  • Kennedy Capital Management first reported a position in Abeona Therapeutics in Q1 2025 and has held it in 7 quarters since.
  • Kennedy Capital Management's Abeona Therapeutics position peaked at $7.66M in Q2 2026.
  • 116 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q3 2026.

Based on Kennedy Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.